Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)

Date

09 Oct 2016

Session

Poster display

Presenters

David Dearnaley

Citation

Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372

Authors

D. Dearnaley1, D.R. Saltzstein2, J.E. Sylvester3, L. Karsh4, B.A. Mehlhaff5, C. Pieczonka6, J.L. Bailen7, D.B. Maclean8, S. Sankoh9, H.M. Faessel10, H.M. Lin11, N.D. Shore12

Author affiliations

  • 1 Academic Radiotherapy, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM25PT - Sutton/GB
  • 2 Clinical Research, Urology San Antonio, 78235 - San Antonio/US
  • 3 Radiation Oncology, 21st Century Oncology, 34202 - Bradenton/US
  • 4 Clinical Research, The Urology Center of Colorado, 80211 - Denver/US
  • 5 Urologic Oncology, Oregon Urology, 97477 - Springfield/US
  • 6 Advanced Therapeutics, Associated Medical Professionals of NY, 13210 - Syracuse/US
  • 7 Clinical Research, First Urology, 47130 - Jeffersonville/US
  • 8 Oncology Clinical Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 02139 - Cambridge/US
  • 9 Global Statistics, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 02139 - Cambridge/US
  • 10 Quantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 11 Global Outcomes Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 02139 - Cambridge/US
  • 12 Urology, Carolina Urologic Research Center, 29572 - Myrtle Beach/US
More

Resources

Abstract 3676

Background

RGX is an investigational, non-peptide gonadotropin-releasing hormone (GnRH) antagonist of the human GnRH receptor (IC50 0.12 nM). This open label, parallel group study evaluated the testosterone (T)-lowering efficacy, safety and PK of RGX vs the injectable peptide GnRH antagonist DGX in pts with PC.

Methods

Men aged ≥18 y with intermediate risk localized PC appropriate for EBRT and 6 mos ADT, with baseline T >150.0 ng/dL, and prostate specific antigen (PSA) >2.0 ng/mL received oral RGX 320.0 mg on d 1 then 120.0 mg once daily (QD) or DGX 240.0 mg on d 1 then 80.0 mg SC Q4W for 24 wks. The primary endpoint was % of pts with castrate T levels

Results

At data cut-off (March 2016) after 24wks, sustained castration rates were 95% in RGX treated pts (N = 65; median age 71.0 y) vs 89% with DGX (N = 38; 70.5 y). Median T with RGX vs DGX were 53.0 ng/dL (23.9–306.8) vs 49.0 ng/dL (23.0–223.9) after 24 h and 7.8 ng/dL (2.9–53.0) vs 10.1 ng/dL (3.2–236.8) after 12 wks. Prostate size reductions at 8-12 wks were similar in both arms, as were PSA change from baseline values (median -91.2% vs -88.6%). (Table.) Sexual activity per PR-25 was partially recovered after stop of treatment in both arms and further QoL analysis is ongoing. No pts discontinued due to Rx-related adverse events, most common were (RGX/DGX): hot flush (57/61%), fatigue (26/16%), and diarrhea (18/13%).

Median (range) Baseline After 24 Wks 4 Wks Post-Rx Discontinuation 8 Wks Post-Rx Discontinuation 12 Wks Post-Rx Discontinuation
RGX LH, IU/L 4.7 (0.8–32.2) 0.1 (0.1–3.9) 3.1 (0.2–15.7) 8.3 (0.1–32.4) 10.7 (0.1–38.7)
DGX LH, IU/L 4.8 (1.3–42.0) 0.1 (0.1–3.7) 0.2 (0.1–2.8) 0.5 (0.1–7.7) 1.4 (0.1–15.7)
RGX T, ng/dL 355.9 (149.0–1290.0) 8.1 (3.2–125.0) 94.0 (2.9–818.8) 238.4 (10.1–929.8) 257.0 (9.5–858.8)
DGX T, ng/dL 404.0 (138.0–937.8) 8.9 (2.9–272.8) 9.7 (2.9–225.0) 16.1 (3.2–263.0) 30.0 (3.7–378.8)
RGX PSA, ug/L 7.3 (2.6–31.5) 0.1 (0.1–1.6) 0.1 (0.1–1.5) 0.19 (0.1–3.2) 0.19 (0.1–2.3)
DGX PSA, ug/L 7.3 (2.5–88.9) 0.1 (0.1–1.8) 0.1 (0.1–2.1) 0.1 (0.1–2.2) 0.07 (0.1–2.0)

Conclusions

Oral RGX and injectable DGX have similar T-lowering and clinical efficacy. Recovery of T levels occur sooner in RGX arm vs DGX. Oral RGX may be a potentially advantageous option for GnRH antagonist therapy and will be further studied vs depot GnRH agonists in phase 3.

Clinical trial identification

NCT02135445

Legal entity responsible for the study

Millennium Pharmaceuticals, Inc.

Funding

Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Disclosure

D.P. Dearnaley: Advisory board (Millennium Pharmaceuticals, Inc., Janssen Pharma).

D.R. Saltzstein: Consultancy/advisory role (Astellas, Bayer, Janssen, Tolmar), Investigator/scientific study/trial (Astellas, Neogenomics, Oncocyte, Tokai), and Meeting participant/lecturer (Astellas, Bayer, Janssen); Research funding (Millennium Pharmaceuticals, Inc., Tokai).

L. Karsh: Consultancy/advisory role (AbbVie, Amgen, Argos, Astellas, Medivation, Bayer, BNIT, Dendreon, Heat Biologics, Janssen, Myriad, Sanofi, Spectum, Swan Valley Medical, Tolmar); Speaker (Astellas/Medivation, Bayer, Dendreon, Janssen); and PI Clinical Trials (Argos, Astellas, Medivation, Augmenix, Auxilium, BNIT, Dendreon, FKD Therapies, Genome DX Biosciences, Genomic Health Inc., Heat Biologics, Janssen, MDx Health, Pfizer, Spectrum,Takeda).

B.A. Mehlhaff: Consultant (AbbVie, Amgen, Astellas, Medivation, Bayer, Dendreon, Janssen, Myriad; Speaker (AbbVie, Amgen, Astellas/Medivation, Bayer, Dendreon, Janssen); PI Clinical Trials (Astellas, Medivation, Augmenix, Bayer, Dendreon, Genomic Health Inc., Janssen, MDx Health, Millennium Pharmaceuticals, Takeda, Tokai).

C. Pieczonka: Research funding (Millennium Pharmaceuticals, Inc., Janssen, Dendreon, Astellas, Bayer); Consultancy/advisory role (Janssen, Bayer); Honoraria and Speakers' Bureau (Janssen, Dendreon, Astellas, Bayer).

J.L. Bailen: Research funding (Astellas, Bayer, Dendreon, Janssen, Medivation, Millennium Pharmaceuticals, Inc.) and Honoraria, Consultancy/advisory role, and Speakers' Bureau (Astellas, Auxilium, Bayer, Dendreon, Janssen, Sanofi).

D.B. MacLean, S. Sankoh, H.M. Faessel and H.M. Lin: Employment (Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)

N.D. Shore: Consultancy/advisory role (Astellas, Bayer, Dendreon, Ferring, Janssen, Medivation, Sanofi); Research funding and Consultancy/advisory role (Millennium Pharmaceuticals, Inc.).

All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings